JP2004534066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534066A5 JP2004534066A5 JP2003504886A JP2003504886A JP2004534066A5 JP 2004534066 A5 JP2004534066 A5 JP 2004534066A5 JP 2003504886 A JP2003504886 A JP 2003504886A JP 2003504886 A JP2003504886 A JP 2003504886A JP 2004534066 A5 JP2004534066 A5 JP 2004534066A5
- Authority
- JP
- Japan
- Prior art keywords
- celecoxib
- pharmaceutically acceptable
- medicament according
- cox
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 16
- 229960000590 celecoxib Drugs 0.000 claims 10
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 229940111134 coxibs Drugs 0.000 claims 9
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 9
- -1 delacoxib Chemical compound 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 229960001534 risperidone Drugs 0.000 claims 7
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 7
- 229960000836 amitriptyline Drugs 0.000 claims 6
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 6
- 239000003176 neuroleptic agent Substances 0.000 claims 5
- 208000028017 Psychotic disease Diseases 0.000 claims 4
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims 4
- 230000001430 anti-depressive effect Effects 0.000 claims 4
- 239000000935 antidepressant agent Substances 0.000 claims 4
- 229940005513 antidepressants Drugs 0.000 claims 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 4
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 3
- BATFHSIVMJJJAF-UHFFFAOYSA-N Morindone Chemical compound OC1=CC=C2C(=O)C3=C(O)C(C)=CC=C3C(=O)C2=C1O BATFHSIVMJJJAF-UHFFFAOYSA-N 0.000 claims 3
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims 3
- 150000008371 chromenes Chemical class 0.000 claims 3
- 229960004945 etoricoxib Drugs 0.000 claims 3
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 3
- 229960002690 fluphenazine Drugs 0.000 claims 3
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims 3
- 229960001929 meloxicam Drugs 0.000 claims 3
- YBCBOXOAJAQPQU-UHFFFAOYSA-N n-(2-cyclohexyloxy-3-nitrophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC([N+]([O-])=O)=C1OC1CCCCC1 YBCBOXOAJAQPQU-UHFFFAOYSA-N 0.000 claims 3
- 229960004662 parecoxib Drugs 0.000 claims 3
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 3
- 229960002702 piroxicam Drugs 0.000 claims 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 229960000371 rofecoxib Drugs 0.000 claims 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 3
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 claims 3
- 229960002004 valdecoxib Drugs 0.000 claims 3
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 3
- 229960000607 ziprasidone Drugs 0.000 claims 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 2
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 2
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 claims 2
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 claims 2
- BVUSNQJCSYDJJG-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 BVUSNQJCSYDJJG-UHFFFAOYSA-N 0.000 claims 2
- QPGGEKPRGVJKQB-UHFFFAOYSA-N 5-[2-(dimethylamino)ethyl]-11-methyl-6-benzo[b][1,4]benzodiazepinone Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 claims 2
- JSXBVMKACNEMKY-UHFFFAOYSA-N 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine;hydron;chloride Chemical compound Cl.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 JSXBVMKACNEMKY-UHFFFAOYSA-N 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 244000025254 Cannabis sativa Species 0.000 claims 2
- 208000024254 Delusional disease Diseases 0.000 claims 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 2
- LRWSFOSWNAQHHW-UHFFFAOYSA-N Fluphenazine enanthate Chemical compound C1CN(CCOC(=O)CCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 LRWSFOSWNAQHHW-UHFFFAOYSA-N 0.000 claims 2
- GUTXTARXLVFHDK-UHFFFAOYSA-N Haloperidol decanoate Chemical compound C1CC(OC(=O)CCCCCCCCC)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 GUTXTARXLVFHDK-UHFFFAOYSA-N 0.000 claims 2
- 241000546188 Hypericum Species 0.000 claims 2
- 235000017309 Hypericum perforatum Nutrition 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 2
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 claims 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims 2
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 claims 2
- 229960000276 acetophenazine Drugs 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 229960003036 amisulpride Drugs 0.000 claims 2
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims 2
- 229960004372 aripiprazole Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 2
- 229960001076 chlorpromazine Drugs 0.000 claims 2
- 229960001552 chlorprothixene Drugs 0.000 claims 2
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims 2
- 229960001653 citalopram Drugs 0.000 claims 2
- 229960004170 clozapine Drugs 0.000 claims 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 2
- 229960003914 desipramine Drugs 0.000 claims 2
- 229960003075 dibenzepin Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 229960005426 doxepin Drugs 0.000 claims 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 2
- 229960000394 droperidol Drugs 0.000 claims 2
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims 2
- 229960002464 fluoxetine Drugs 0.000 claims 2
- 229960002419 flupentixol Drugs 0.000 claims 2
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 claims 2
- 229960001374 fluphenazine decanoate Drugs 0.000 claims 2
- 229960000787 fluphenazine enanthate Drugs 0.000 claims 2
- 229960004038 fluvoxamine Drugs 0.000 claims 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 2
- 229960003878 haloperidol Drugs 0.000 claims 2
- 229960005007 haloperidol decanoate Drugs 0.000 claims 2
- 229960001345 haloperidol lactate Drugs 0.000 claims 2
- 229960004801 imipramine Drugs 0.000 claims 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 2
- 229960000423 loxapine Drugs 0.000 claims 2
- 229960004990 loxapine hydrochloride Drugs 0.000 claims 2
- 229960000589 loxapine succinate Drugs 0.000 claims 2
- 229960004090 maprotiline Drugs 0.000 claims 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 2
- 229960000300 mesoridazine Drugs 0.000 claims 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims 2
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 claims 2
- 229940042053 methotrimeprazine Drugs 0.000 claims 2
- 229960003955 mianserin Drugs 0.000 claims 2
- 229960001785 mirtazapine Drugs 0.000 claims 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 2
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims 2
- 229960004644 moclobemide Drugs 0.000 claims 2
- 229960001800 nefazodone Drugs 0.000 claims 2
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 2
- 229960001158 nortriptyline Drugs 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 2
- 229960002296 paroxetine Drugs 0.000 claims 2
- 229960000762 perphenazine Drugs 0.000 claims 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims 2
- 229960003634 pimozide Drugs 0.000 claims 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims 2
- 229960003111 prochlorperazine Drugs 0.000 claims 2
- 229960003598 promazine Drugs 0.000 claims 2
- 229960004431 quetiapine Drugs 0.000 claims 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 2
- 229960005197 quetiapine fumarate Drugs 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims 2
- 229960002073 sertraline Drugs 0.000 claims 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 2
- 229960002784 thioridazine Drugs 0.000 claims 2
- 229960000882 thiothixene hydrochloride Drugs 0.000 claims 2
- 208000016686 tic disease Diseases 0.000 claims 2
- 229960005013 tiotixene Drugs 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 229960003991 trazodone Drugs 0.000 claims 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 2
- 229960002324 trifluoperazine Drugs 0.000 claims 2
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 claims 2
- 229960003904 triflupromazine Drugs 0.000 claims 2
- 229960002431 trimipramine Drugs 0.000 claims 2
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims 2
- 229960004688 venlafaxine Drugs 0.000 claims 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 2
- 229960001255 viloxazine Drugs 0.000 claims 2
- ZERWDZDNDJBYKA-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O ZERWDZDNDJBYKA-UHFFFAOYSA-N 0.000 claims 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 1
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960001258 fluphenazine hydrochloride Drugs 0.000 claims 1
- 229960000443 hydrochloric acid Drugs 0.000 claims 1
- 229960004391 lorazepam Drugs 0.000 claims 1
- 229960004684 molindone hydrochloride Drugs 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 229960003252 pipotiazine Drugs 0.000 claims 1
- JOMHSQGEWSNUKU-UHFFFAOYSA-N pipotiazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 JOMHSQGEWSNUKU-UHFFFAOYSA-N 0.000 claims 1
- 229960000652 sertindole Drugs 0.000 claims 1
- 229940125725 tranquilizer Drugs 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- 229960004141 zuclopenthixol Drugs 0.000 claims 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10129320A DE10129320A1 (de) | 2001-06-19 | 2001-06-19 | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| US36490402P | 2002-03-14 | 2002-03-14 | |
| PCT/EP2002/006013 WO2002102297A2 (en) | 2001-06-19 | 2002-05-31 | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008188890A Division JP4824727B2 (ja) | 2001-06-19 | 2008-07-22 | 精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのｃｏｘ−２阻害薬の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534066A JP2004534066A (ja) | 2004-11-11 |
| JP2004534066A5 true JP2004534066A5 (enExample) | 2005-12-22 |
| JP4205577B2 JP4205577B2 (ja) | 2009-01-07 |
Family
ID=26009543
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003504886A Expired - Fee Related JP4205577B2 (ja) | 2001-06-19 | 2002-05-31 | 精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのｃｏｘ−２阻害薬の使用 |
| JP2008188890A Expired - Fee Related JP4824727B2 (ja) | 2001-06-19 | 2008-07-22 | 精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのｃｏｘ−２阻害薬の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008188890A Expired - Fee Related JP4824727B2 (ja) | 2001-06-19 | 2008-07-22 | 精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのｃｏｘ−２阻害薬の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040204469A1 (enExample) |
| EP (2) | EP1627639B1 (enExample) |
| JP (2) | JP4205577B2 (enExample) |
| AP (1) | AP1512A (enExample) |
| AT (2) | ATE452642T1 (enExample) |
| AU (1) | AU2002312967A1 (enExample) |
| CA (1) | CA2448025C (enExample) |
| CY (1) | CY1109949T1 (enExample) |
| DE (2) | DE60234873D1 (enExample) |
| DK (2) | DK1627639T3 (enExample) |
| EA (1) | EA009780B1 (enExample) |
| ES (2) | ES2336682T3 (enExample) |
| OA (1) | OA12627A (enExample) |
| PT (2) | PT1397145E (enExample) |
| SI (1) | SI1627639T1 (enExample) |
| WO (1) | WO2002102297A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| ATE420647T1 (de) * | 2002-11-26 | 2009-01-15 | Alexza Pharmaceuticals Inc | Verwendung von loxapine für die herstellung eines mittels zur behandlung von schmerz |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| EP1633360A1 (en) * | 2003-05-16 | 2006-03-15 | Pfizer Products Incorporated | Treatment of psychotic and depressive disorders |
| US20040234914A1 (en) | 2003-05-21 | 2004-11-25 | Alexza Molecular Delivery Corporation | Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same |
| US20060241188A1 (en) * | 2003-08-27 | 2006-10-26 | Elililly And Company | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors |
| JP2007511572A (ja) * | 2003-11-19 | 2007-05-10 | グラクソ グループ リミテッド | 統合失調症治療のためのシクロオキシゲナーゼ−２選択的阻害剤の使用 |
| JP2007511569A (ja) * | 2003-11-19 | 2007-05-10 | グラクソ グループ リミテッド | 鬱病性障害の治療用のシクロオキシゲナーゼ−２阻害剤の使用 |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| EP1725222A2 (en) * | 2004-03-02 | 2006-11-29 | Pharmacia Corporation | Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| US7581540B2 (en) | 2004-08-12 | 2009-09-01 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
| US20070281927A1 (en) * | 2006-06-06 | 2007-12-06 | Shanthakumar Tyavanagimatt | Anti-inflammatory and analgesic compositions and related methods |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| JP5144104B2 (ja) | 2007-04-09 | 2013-02-13 | ユニ・チャーム株式会社 | 伸縮性複合シート及びそれを用いた使い捨て着用物品 |
| JP2013507394A (ja) * | 2009-10-09 | 2013-03-04 | プロセラ インコーポレイテッド | 自閉症スペクトル障害と診断されたヒトにおいて自閉症スペクトル障害に関連する少なくとも一つの症状を低減するための、ペディオコッカス属を含む組成物及び方法 |
| EP2340819A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising venlafaxine and celecoxib in the treatment of pain |
| EP2340818A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of venlafaxine and celecoxib |
| MX2020005517A (es) | 2017-12-05 | 2020-11-09 | Sunovion Pharmaceuticals Inc | Formas cristalinas y metodos de produccion de las mismas. |
| JP7268026B2 (ja) | 2017-12-05 | 2023-05-02 | サノビオン ファーマシューティカルズ インク | 非ラセミ混合物およびその使用 |
| KR102852740B1 (ko) | 2018-02-02 | 2025-08-29 | 알렉스자 파마스티칼즈, 인크. | 전기적 응축 에어로졸 디바이스 |
| US11160758B2 (en) | 2019-06-04 | 2021-11-02 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579846A (en) * | 1984-10-11 | 1986-04-01 | Pfizer Inc. | Antiinflammatory compositions and methods |
| AU1041599A (en) * | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
| PL196996B1 (pl) * | 1999-07-01 | 2008-02-29 | Upjohn Co | Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku |
| EP1142889A1 (en) * | 2000-04-03 | 2001-10-10 | Pfizer Products Inc. | Pyrazole derivatives as anti-inflammatory/analgesic agents |
| US6306842B1 (en) * | 2000-06-02 | 2001-10-23 | Medinox, Inc. | Protected forms of a combination of pharmacologically active agents and uses therefor |
-
2002
- 2002-05-31 DK DK05024864.0T patent/DK1627639T3/da active
- 2002-05-31 AU AU2002312967A patent/AU2002312967A1/en not_active Abandoned
- 2002-05-31 PT PT02738138T patent/PT1397145E/pt unknown
- 2002-05-31 AT AT05024864T patent/ATE452642T1/de active
- 2002-05-31 JP JP2003504886A patent/JP4205577B2/ja not_active Expired - Fee Related
- 2002-05-31 WO PCT/EP2002/006013 patent/WO2002102297A2/en not_active Ceased
- 2002-05-31 DE DE60234873T patent/DE60234873D1/de not_active Expired - Lifetime
- 2002-05-31 ES ES05024864T patent/ES2336682T3/es not_active Expired - Lifetime
- 2002-05-31 DE DE60214542T patent/DE60214542T2/de not_active Expired - Lifetime
- 2002-05-31 PT PT05024864T patent/PT1627639E/pt unknown
- 2002-05-31 CA CA2448025A patent/CA2448025C/en not_active Expired - Fee Related
- 2002-05-31 EP EP05024864A patent/EP1627639B1/en not_active Expired - Lifetime
- 2002-05-31 US US10/480,600 patent/US20040204469A1/en not_active Abandoned
- 2002-05-31 SI SI200230890T patent/SI1627639T1/sl unknown
- 2002-05-31 AP APAP/P/2003/002934A patent/AP1512A/en active
- 2002-05-31 EP EP02738138A patent/EP1397145B1/en not_active Expired - Lifetime
- 2002-05-31 ES ES02738138T patent/ES2271269T3/es not_active Expired - Lifetime
- 2002-05-31 AT AT02738138T patent/ATE338557T1/de active
- 2002-05-31 DK DK02738138T patent/DK1397145T3/da active
- 2002-05-31 EA EA200301291A patent/EA009780B1/ru not_active IP Right Cessation
- 2002-05-31 OA OA1200300328A patent/OA12627A/en unknown
-
2008
- 2008-07-22 JP JP2008188890A patent/JP4824727B2/ja not_active Expired - Fee Related
-
2010
- 2010-03-22 CY CY20101100270T patent/CY1109949T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534066A5 (enExample) | ||
| CA2448025A1 (en) | Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders | |
| US20040082543A1 (en) | Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain | |
| US5616593A (en) | Compositions containing piperine | |
| JP2008531715A5 (enExample) | ||
| EP1633400A2 (en) | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines | |
| JP2015516395A5 (enExample) | ||
| ES2705726T3 (es) | Métodos para tratar el aumento de peso inducido por antipsicóticos | |
| US20050119249A1 (en) | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
| CN102781431A (zh) | 兽医组合物 | |
| CA2601509A1 (en) | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions | |
| JP2022051745A5 (enExample) | ||
| US8088814B2 (en) | Methods and compositions for the treatment of psychiatric disorders | |
| WO2006100213A1 (en) | Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor | |
| ES2267943T3 (es) | Metodos de uso de derivados pirrolicos contra el trastorno obsesivo compulsivo. | |
| TWI455712B (zh) | 增強神經藥方療效的山梨酸與苯甲酸及其衍生物 | |
| PT1397128E (pt) | Agonista opiáceo kapa para o tratamento de doenças da bexiga irritável. | |
| US20110130390A1 (en) | Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders | |
| CN100467064C (zh) | 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用 | |
| CA2461248C (en) | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists | |
| US20060167074A1 (en) | Methods and compositions for the treatment of psychiatric disorders | |
| EP1545546B1 (en) | Treatment of dyskinesia with 2,3-benzodiazepines | |
| ES2701975A2 (es) | Uso de ligandos del receptor sigma en el dolor post-herpetico | |
| US20080139573A1 (en) | Treatment of resistant Schizophrenia and other CNS disorders | |
| WO2022265984A1 (en) | Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders |